Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes

Haematologica

Volumn 97, Issue 8, 2012, Pages 1149-1157

  Gerrits, Anja J ^a   Gitz, Eelo ^a   Koekman, Cornelis A ^a   Visseren, Frank L ^a   van Haeften, Timon W ^a   Akkerman, Jan Willem N ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adipokines; Insulin; Insulin resistance; Megakaryocytes; Obesity; Platelets; Type 2 diabetes

Indexed keywords

F ACTIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LEPTIN; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RETINOL BINDING PROTEIN 4; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INSULIN RESISTANCE; MEGAKARYOCYTE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADIPOKINES; BLOOD PLATELETS; CALCIUM; CELL LINE; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LEPTIN; MALE; MEGAKARYOCYTES; METABOLIC SYNDROME X; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RETINOL-BINDING PROTEINS, PLASMA;

EID: 84864742249     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.054916     Document Type: Article

References (54)

1. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378-84.
2. Fateh-Moghadam S, Li Z, Ersel S, Reuter T, Htun P, Plöckinger U, et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol. 2005;25 (6):1299-303.
3. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the 1156missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270-87.
4. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2002;105 (18):2231-9.
5. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 1991;17(4):433-8.
6. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26(2):417-22.
7. Turk Z, Flego I, Kerum G. Platelet aggregation in type 1 diabetes without microvascular disease during continuous subcutaneous insulin infusion. Horm Metab Res. 1996; 28(2):95-100.
8. Pignone M, Williams CD. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol. 2010;6(11):619-28.
9. Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem. 2004;279(5):3254-64.
10. Gerrits AJ, Koekman CA, Yildirim C, Nieuwland R, Akkerman JW. Insulin inhibits tissue factor expression in monocytes. J Thromb Haemost. 2009;7(1):198-205.
11. Gerrits AJ, Koekman CA, van Haeften TW, Akkerman JW. Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes. 2010;59(6): 1487-95.
12. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444 (7121): 881-7.
13. Gualillo O, Gonzalez-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med. 2007;17(8):275-83.
14. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444(7121):840-6.
15. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis. 2009;19(6):440-9.
16. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest. 2001;108(10):1533-40.
17. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes. 1999;48(2):426-9.
18. Canavan B, Salem RO, Schurgin S, Koutkia P, Lipinska I, Laposata M, et al. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab. 2005;90(10): 5779-85.
19. Ozata M, Avcu F, Durmus O, Yilmaz I, Ozdemir IC, Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency. Obes Res. 2001; 9(10):627-30.
20. den Dekker DE, Gorter G, Heemskerk JW, Akkerman JW. Development of platelet inhibition by cAMP during megakaryocytopoiesis. J Biol Chem. 2002;277(32):29321-9.
21. Fugman DA, Witte DP, Jones CL, Aronow BJ, Lieberman MA. In vitro establishment and characterization of a human megakaryoblastic cell line. Blood. 1990;75(6):1252-61.
22. Jones CL, Witte DP, Feller MJ, Fugman DA, Dorn GW 2nd, Lieberman MA. Response of a human megakaryocytic cell line to thrombin: increase in intracellular free calcium and mitogen release. Biochim Biophys Acta. 1992;1136(3):272-82.
23. van der Vuurst H, van Willigen G, van Spronsen A, Hendriks M, Donath J, Akkerman JW. Signal transduction through trimeric G proteins in megakaryoblastic cell lines. Arterioscler Thromb Vas Biol. 1997;17 (9):1830-6.
24. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Olijhoek JK, Visseren FL. Lipidlowering therapy does not affect the postprandial drop in high density lipoproteincholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial. Clin Endocrinol. 2008;69(6):870-7.
25. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292-5.
26. de Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Bellioo D, Conde R. Effects of a low-fat carbohydrate diet on adipocytokines in obese adults. Horm Res. 2007;67(6):296-300.
27. Weikert C, Westphal S, Berger K, Dierkes J, Möhlig M, Spranger J, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab. 2008;93(7):2647-53.
28. Lehrke M, Reilly MP, Millington SC, Igbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. Plos Med. 2004;1:e45.
29. Ogawa W, Matozaki T, Kasuga M. Role of binding proteins to IRS-1 in insulin signalling. Mol Cell Biochem. 1998;182(1-2):13-22.
30. Kroner C, Eybrechts K, Akkerman JW. Dual regulation of platelet protein kinase B. J Biol Chem. 2000; 275(36):27790-8.
31. van der Meijden PE, Schoenwaelder SM, Feijge MA, Cosemans JM, Munnix IC, Wetzker R. Dual P2Y 12 receptor signaling in thrombin-stimulated platelets-involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity. FEBS J. 2008;275 (2):371-85.
32. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem. 2004;279(6):4186-95.
33. Hardy AR, Jones ML, Mundell SJ, Poole AW. Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets. Blood. 2004;104 (6): 1745-52.
34. Bouscary D, Lecoq-Lafon C, Chrétien S, Zompi S, Fichelson S, Muller O, et al. Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo) Oncogene. 2001;20(18):2197-204.
35. Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci. 2000;113(Pt 16): 2813-9.
36. Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Hegele RA, et al. Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care. 2008;31 (7):1410-5.
37. McNeely MJ, Boyko EJ, Weigle DS, Shofer JB, Chessler SD, Leonnetti DL, et al. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Car.e 1999;22(1):65-70.
38. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131-7.
39. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354(24):2552-63.
40. Dorn GW 2nd, Davis MG. Differential megakaryocytic desensitization to platelet agonists. Am J Physiol. 1992;263(4 Pt1): C864-72.
41. Danielsson A, Ost A, Nystrom FH, Stralfors P. Attenuation of insulin-stimulated insulin receptor substrate-1 serine 307 phosphorylation in insulin resistance of type 2 diabetes. J Biol Chem. 2005;280(41):34389-92.
42. Ost A, Danielsson A, Lidén M, Eriksson U, Nystrom FH, Strålfors P. Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. FASEB J. 2007;21(13): 3696-704.
43. Tanti TF, Jager J. Cellular mechanism of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol. 2009;9(6):753-62.
44. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. 2009;296(4):E581-91.
45. Luo M, Langlais P, Yi Z, Lefort N, De Filippis EA, Hwang H, et al. Phosphorylation of human insulin receptor substrate-1 at Serine 629 plays a positive role in insulin signaling. Endocrinology. 007;148(10):4895-905.
46. Paz K, Liu YF, Shorer H, Hemi R, LeRoith D, Quan M, et al. Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem. 1999;274(40):28816-22.
47. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim H, et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci USA. 1996;93 (16):8374-8.
48. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277(44): 42394-8.
49. Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA. 1997;94(8):4171-5.
50. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148(1):241-51.
51. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278:45777-84.
52. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun. 2003;311(2):372-9.
53. Carvalho E, Jansson PA, Axelsen M, Eriksson JW, Huang X, Groop L, Rondinone C, Sjöström L, Smith U. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. FASEB J. 1999; 13(15):2173-8.
54. Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway. Blood. 2007;110(13):4243-52.